Cargando…
ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1
Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development of a range of ERK1/2 inhibitors (ERKi) that either inhibit kinase catalytic activity (catERKi) or...
Autores principales: | Balmanno, Kathryn, Kidger, Andrew M., Byrne, Dominic P., Sale, Matthew J., Nassman, Nejma, Eyers, Patrick A., Cook, Simon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212521/ https://www.ncbi.nlm.nih.gov/pubmed/37018014 http://dx.doi.org/10.1042/BCJ20220598 |
Ejemplares similares
-
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
por: Sale, Matthew J., et al.
Publicado: (2019) -
ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation
por: de Jong, Petrus R., et al.
Publicado: (2016) -
Isoform-Specific Roles of ERK1 and ERK2 in Arteriogenesis
por: Ricard, Nicolas, et al.
Publicado: (2019) -
ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1
por: Buscà, Roser, et al.
Publicado: (2015) -
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
por: Cook, Simon J., et al.
Publicado: (2022)